No Data
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's Is How to Trade